CSIMarket
 
Interpace Biosciences Inc   (PDII)
 

Interpace Biosciences Inc's Suppliers Performance

PDII's Supply Chain




 
PDII Costs vs Sales of Suppliers Growth Interpace Biosciences Inc recorded an increase in cost of sales by 15.93 % year on year, sequentially cost of sales grew by 15.93 % in Q2.

More on PDII Suppliers



Interpace Biosciences Inc recorded increase in cost of sales by 15.93 % year on year, sequentially cost of sales grew by 15.93 % in Q2.

More on PDII Suppliers




Interpace Biosciences Inc's Comment on Supply Chain


The company procures reagents, equipment, and other testing materials primarily from sole suppliers, including components for collection kits sourced from sole-source suppliers. Key suppliers include Thermo Fisher Scientific Inc., Illumina, Inc., Qiagen N.V., Mettler-Toledo Rainin, LLC., and F. Hoffmann-La Roche AG. Although the company has developed alternate sourcing strategies, it cannot guarantee their effectiveness or availability. Interruptions in supply or quality issues could disrupt test processing, delay patient reports, increase costs, and negatively affect customer relationships. To mitigate these risks, the company maintains higher inventory levels, which may result in excess supplies if test volumes decline or suppliers change. Supply challenges may also occur during the introduction of new tests as volumes increase.

Interpace Biosciences Inc's Comment on Supply Chain


The company procures reagents, equipment, and other testing materials primarily from sole suppliers, including components for collection kits sourced from sole-source suppliers. Key suppliers include Thermo Fisher Scientific Inc., Illumina, Inc., Qiagen N.V., Mettler-Toledo Rainin, LLC., and F. Hoffmann-La Roche AG. Although the company has developed alternate sourcing strategies, it cannot guarantee their effectiveness or availability. Interruptions in supply or quality issues could disrupt test processing, delay patient reports, increase costs, and negatively affect customer relationships. To mitigate these risks, the company maintains higher inventory levels, which may result in excess supplies if test volumes decline or suppliers change. Supply challenges may also occur during the introduction of new tests as volumes increase.







PDII's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Interpace Biosciences Inc 0.00 35.66 23.65 102
SUBTOTAL 0.00 0.00 0.00 -


Sources: Interpace Biosciences Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Interpace Biosciences Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.